Valuation: SpectraCure AB

Market Cap 18.26M 1.88M 1.65M 1.54M 1.41M 2.65M 181M 2.69M 7.13M 89.13M 7.07M 6.91M 308M P/E 2024
-10.6x
P/E 2025 -0.79x
Enterprise Value 7.52M 776K 681K 634K 581K 1.09M 74.7M 1.11M 2.94M 36.72M 2.91M 2.85M 127M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
28.39%
Yield 2024 *
-
Yield 2025 -
1 day-0.62%
1 week-37.86%
Current month-41.82%
1 month-27.77%
3 months-54.80%
6 months-68.50%
Current year-79.46%
1 week 0.03
Extreme 0.0308
0.05
1 month 0.03
Extreme 0.0308
0.09
Current year 0.03
Extreme 0.0308
0.17
1 year 0.03
Extreme 0.0308
0.32
3 years 0.03
Extreme 0.0308
6
5 years 0.03
Extreme 0.0308
12
10 years 0.03
Extreme 0.0308
45.15
Manager TitleAgeSince
Chief Executive Officer 54 2025-09-30
Director of Finance/CFO - 2026-05-31
Chief Tech/Sci/R&D Officer - 2025-10-06
Director TitleAgeSince
Director/Board Member 63 2012-08-30
Director/Board Member 72 2021-12-31
Chairman 74 2021-12-31
Date Insider Type Main position Quantity % Market Cap.
5/26/23 Buy

Chairman

25,000 0.0257%
8/30/22 Buy

Director

25,000 0.0257%
7/9/22 Sell

Director

1,048,493 1.0795%
Change 5-day change 1-year change 3-year change Capi.($)
-0.62%-37.86%-81.26%-99.45% 1.88M
+0.77%-4.58%+28.16%+45.34% 1.42B
-0.16%+5.04%-43.69%-45.41% 280M
+1.92%+3.92%+32.50%-11.67% 55.64M
-1.39%-1.84%-13.41%-51.37% 51.52M
Average +0.10%-7.06%-15.54%-32.51% 362.7M
Weighted average by Cap. +0.60%-2.79%+15.91%+26.69%

Financials

2024 2025
Net sales - -
Net income -23M -2.37M -2.08M -1.94M -1.78M -3.34M -228M -3.39M -8.99M -112M -8.9M -8.71M -388M -56.08M -5.78M -5.08M -4.72M -4.33M -8.14M -557M -8.27M -21.91M -274M -21.7M -21.24M -946M
Net Debt -13.13M -1.35M -1.19M -1.11M -1.01M -1.91M -130M -1.94M -5.13M -64.09M -5.08M -4.97M -222M -10.74M -1.11M -972K -904K -830K -1.56M -107M -1.58M -4.19M -52.41M -4.16M -4.07M -181M
Logo SpectraCure AB
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Employees
13
Date Price Change Volume
26-07-24 SEK 0.0320 -0.62% 2,203,985
26-07-23 SEK 0.0322 -0.92% 2,229,833
26-07-22 SEK 0.0325 -18.34% 10,741,036
26-07-21 SEK 0.0398 -7.44% 3,606,363
26-07-20 SEK 0.0430 -16.50% 3,734,937
  1. Stock Market
  2. Stocks
  3. SPEC Stock